A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer
Dabrafenib is a potent and selective inhibitor of BRAF kinase activity. This is a Phase II,
non-randomized, open-label study to assess the efficacy, safety, and tolerability of
dabrafenib administered as a single agent and in combination with trametinib in stage IV
disease to subjects with BRAF mutant advanced non-small cell lung cancer. Subjects will
receive dabrafenib 150 mg twice daily (BID) in monotherapy treatment and dabrafenib 150 mg
bid and trametinib 2 mg once daily in combination therapy and continue on treatment until
disease progression, death, or unacceptable adverse event.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.